【摘要】 目的探讨乳腺癌中增殖细胞核抗原(Ki67)、人表皮生长因子-2(C-erbB-2)、血管内皮生长因子(VEGF)的表达与临床病理因素的关系及临床意义。方法采用免疫组化法检测42例乳腺癌标本Ki67、C-erbB-2、VEGF的表达,并与临床病理因素进行相关性分析。结果在42例乳腺癌中,Ki67的表达与乳腺癌临床分期相关(P<0.05);C-erbB-2的表达与乳腺癌临床分期、淋巴结转移状况有关(均P<0.05);VEGF的表达与淋巴结转移状况相关(P<0.05);Ki67和C-erbB-2、Ki67和VEGF的共同表达阳性均与乳腺癌临床分期、淋巴结转移状况显著相关(均P<0.05)。结论Ki67、C-erbB-2和VEGF的阳性表达可以作为乳腺癌发生、发展的评价指标,三者联合检测更加有助于乳腺癌患者的临床治疗和预后判断。更多还原

【Abstract】 Objective To investigate the expression of Ki67,C-erbB-2 and VEGF in breast cancer,and to explore its relationship with clinicopathological factors and its clinical significance.MethodsThe expression of Ki67,C-erbB-2 and VEGF in 42 cases of breast cancer was assessed by immunohistochemistry,and their correlations with clinicopathological factors were statistically analyzed.ResultsIn 42 cases of breast cancer,the expression of Ki67 was related with clinical stage(P<0.05);the expression of C-erbB-2 was related with clinical stage and lymph node status(P<0.05);the expression of VEGF was related with lymph node status(P<0.05).The co-expression of Ki67 and C-erbB-2,Ki67 and VEGF was related to clinical stage and lymph node metastasis(P<0.05).ConclusionKi67,C-erbB-2 and VEGF may be biological markers for estimating the occurrence and progression of breast cancer.Combined detection of Ki67,C-erbB-2 and VEGF may contribute to clinical treatment and prognostic judgment of breast cancer.更多还原